Protagonist Therapeutics ...

51.14
-1.39 (-2.65%)
At close: Mar 25, 2025, 3:59 PM
50.91
-0.44%
Pre-market: Mar 26, 2025, 04:43 AM EDT
-2.65%
Bid 48.76
Market Cap 3.14B
Revenue (ttm) 433.14M
Net Income (ttm) 274.37M
EPS (ttm) 4.23
PE Ratio (ttm) 12.09
Forward PE -47.74
Analyst Buy
Ask 60
Volume 550,151
Avg. Volume (20D) 951,830
Open 52.60
Previous Close 52.53
Day's Range 50.75 - 53.43
52-Week Range 24.22 - 60.60
Beta 2.33

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorder...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2016
Employees 126
Stock Exchange NASDAQ
Ticker Symbol PTGX
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for PTGX stock is "Buy." The 12-month stock price forecast is $61, which is an increase of 19.28% from the latest price.

Stock Forecasts

Next Earnings Release

Protagonist Therapeutics Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+45.89%
Protagonist Therapeutics shares are trading higher... Unlock content with Pro Subscription
3 weeks ago
+2.42%
Protagonist Therapeutics shares are trading higher after the company announced its Polycythemia Vera Phase 3 study with Takeda met all its key goals.